SAN FRANCISCO, Feb. 8 /PRNewswire-FirstCall/ -- Osteologix, Inc. announced today that Charles J. Casamento, CEO and President of Osteologix Inc., will present an overview of the company and its new product under development for the treatment of osteoporosis at the Red Chip Phoenix Small-Cap Investor Conference (“Discovering Tomorrow’s Blue Chips, Today"(TM)) in Phoenix, Arizona on Monday, February 12th at 9:00 am local time. The presentation will be webcast live and will be available at http://www.modavox.com/events/redchip/0207/room1/ . It will also be archived after the presentation for a limited time at www.redchip.com and on the company’s website at www.osteologix.com .
About Osteologix
Osteologix develops proprietary therapeutics for the treatment of important unmet medical needs in bone disease and women’s health. The Company’s lead product, NB S101, has entered phase II clinical trials for the treatment of osteoporosis. Based on the Company’s own data as well as data from phase III clinical trials conducted on another salt of strontium that is approved for sale in Europe, Osteologix believes that NB S101 increases new bone formation and decreases bone resorption. Osteologix further believes that NB S101 will provide patients with greater convenience and fewer side effects than drugs currently approved for osteoporosis in the United States, Europe and elsewhere, thereby addressing the need for an osteoporosis drug with higher compliance rates and better long term efficacy. The Company is not aware of any osteoporosis drug currently approved for sale in the United States that simultaneously increases bone formation and decreases bone resorption. Osteologix is committed to creating value by building a world- class team, accelerating the development of lead product candidates, expanding its pipeline by being the alliance partner of choice, and nurturing a unique company culture. Additional information on Osteologix can be obtained on the Company’s website, www.osteologix.com .
FORWARD-LOOKING STATEMENTS:
Certain of the statements set forth in this press release constitute “Forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words “estimate,” “project,” “intend,” “forecast,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will,” “will likely,” “should,” “could,” “would,” “may” or words or expressions of similar meaning. All such forward looking statements involve risks and uncertainties, including, but not limited to: statements regarding Osteologix’s research and development programs; proposed marketing and sales; patents and regulatory approvals; the effect of competition and proprietary rights of third parties; the need for and availability of additional financing and access to capital; and the seeking of joint development, licensing or distribution and collaboration and marketing arrangements with pharmaceutical companies. There can be no assurance that such forward-looking statements will prove to be accurate and Osteologix undertakes no obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements.
Osteologix, Inc.
CONTACT: Charles J. Casamento, CEO and President, +1-415-955-2726, orMatthew M. Loar, Chief Financial Officer, +1-415-955-2720, both ofOsteologix, Inc.
Web site: http://www.osteologix.com/
